Estrogen receptor-positive breast carcinomas in younger women are different from those of older women: A pathological and immunohistochemical study

Autor(es)

Bacchi, L. M. ^[1] ; Corpa, M. ; Santos, P. P. ^[1] ; Bacchi, C. E. ; Carvalho, F. M. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Fac Med, Dept Pathol, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: BREAST; v. 19, n. 2, p. 137-141, APR 2010.
• Citações Web of Science: 17

Resumo

The higher frequency of triple-negative and HER-2-positive tumors detected in younger patients has been suggested as an explanation for the more aggressive tumor types observed in this age group. However, estrogen receptor (ER)-positive tumors are the most frequent subtype of breast carcinomas identified, even in younger patients. In this retrospective study, the morphological and immunohistochemical profiles of ER-positive breast carcinomas from women 35 yrs and younger that were diagnosed between 1997 and 2007 were evaluated. From these cases, 213 were selected based on the availability of pathology reports and paraffin blocks. For comparison, 117 consecutive cases of breast carcinomas diagnosed in patients >60 yrs from 2006 were included. Paraffin-embedded tumors were stained for expression of ER, progesterone receptor (PR), human epidermal growth factor receptor 2 (HER-2). Ki-67 antigen, epidermal growth factor receptor (EGFR), cytokeratin 5/6, p53, vimentin, CD117, and p63 using tissue microarrays. ER-positive carcinomas were diagnosed in 120 (56.1%) samples of the younger patient group and in 92 (78.6%) samples of the older patient group. Of these ER-positive carcinomas, 48 (40%) from the younger patient group presented the subtype luminal A, compared with 53 (57.6%) from the older patient group (p=0.01). Tumors from the younger patient group were also associated with increased vascular involvement, co-expression of HER-2, and decreased expression of CD117. These results highlight differences in expression markers and the pathology of ER-positive tumors detected in younger women, with a notable characteristic being co-expression of HER-2. (C) 2010 Elsevier Ltd. All rights reserved. (AU)

• Processo FAPESP: 07/51613-1 - Câncer de mama em pacientes brasileiras jovens (menor ou igual a 35 anos): comparação dos achados anátomo-clínicos, incluindo fatores prognósticos e preditivos, com câncer de mama em mulheres idosas (maior que 60 anos)
• Beneficiário: Livia Moscardi Bacchi
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica